Financial Performance Highlights (FY 2025-26)
Kwality Pharmaceuticals Limited reported exceptional financial results for FY26 with revenue from operations growing 36% to ₹503.08 crore (₹370.20 crore in FY25) and profit after tax surging 69% to ₹67.35 crore (₹39.89 crore in FY25). The company achieved its three-year target of doubling business from ₹250 crore in FY23. EBITDA margins expanded by approximately 200 basis points from 22% to 24%, while basic and diluted EPS stood at ₹64.90 (₹38.44 in FY25).
Operational and Strategic Developments
The company expanded its biologics pipeline with three new monoclonal antibodies (biosimilars) and completed 30-40 oncology product registrations. Facilities maintained EU-GMP compliance through multiple international regulatory audits. The company participated in over 15 global pharmaceutical exhibitions across Latin America, Africa, GCC, MENA, and Asia. Debtor days remained elevated at 208 due to Middle East/West Asia conflicts affecting supply chains, though the cash conversion cycle improved from 208 days to 170 days through tightened inventory management.
Balance Sheet and Cash Flow Analysis
Total assets expanded 32% to ₹592.21 crore (₹447.27 crore in FY25), with trade receivables growing 81% to ₹280.05 crore (₹154.31 crore in FY25). Cash reserves declined sharply to ₹0.74 crore from ₹12.02 crore in the previous year. Borrowings increased to ₹130.47 crore from ₹112.45 crore. The cash flow from operating activities was ₹16.59 crore compared to ₹52.72 crore in FY25, reflecting working capital pressures.
AGM and Corporate Governance Matters
The company will hold its 43rd AGM virtually on August 31, 2026, with agenda items including reappointment of directors and remuneration approvals. The board comprises 10 Directors including Executive, Non-Executive, Independent and Women Directors, with 12 Board meetings held during FY26. Secretarial and statutory audit reports contained no qualifications or adverse remarks.
Risks and Contingencies
The company faces significant GST litigation totaling ₹36.97 crore, including ₹6.30 crore demand for alleged erroneous IGST refund and ₹30.26 crore show cause notice for alleged wrongful ITC availment (FY2017-18 to 2022-23). The company recognized ₹0.83 crore as exceptional item due to Labour Code implementation impact on gratuity liability.
Guidance and Outlook
Management raised FY27 revenue guidance to over ₹700 crore (from earlier ₹650 crore) with profitability expected to scale in tandem. Long-term target of ₹1,000 crore plus topline by FY29 remains intact, with potential upside depending on pace of approvals, registrations, and commercialization across priority markets. No dividend was recommended for FY26 to conserve resources for growth initiatives.